LDE-225 Diphosphate
|
- ₹0
- Product name: LDE-225 Diphosphate
- CAS: 1218778-77-8
- MF: C26H32F3N3O11P2
- MW: 681.4885116
- EINECS:
- MDL Number:MFCD16627994
- Synonyms:LDE225 Diphosphate, >=98%;Erismodegib Diphosphate, NVP-LDE225 (diphosphate salt);ErisModegib Diphosphate;LDE 225 Diphosphate;LDE225 (Diphosphate);LDE-225 Diphosphate;NVP-LDE 225 Diphosphate;LDE 225 phosphate
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
storage temp. :Store at -20°C
solubility :≥27.85 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form :White solid.
color :White to off-white
solubility :≥27.85 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
form :White solid.
color :White to off-white
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|
Description
Hedgehog (Hh) proteins, important regulators of development, bind the cell-surface protein Patched, allowing activation of the GPCR-like receptor, Smoothened (SMO). In vertebrates, this ultimately leads to the activation of the zinc-finger transcription factors of the Gli family. Overactivation of this pathway contributes to certain cancers. LDE225 is an Hh signaling pathway inhibitor that acts by antagonizing SMO (IC50s = 1.3 and 2.5 nM for mouse and human, respectively). A dose of 20 mg/kg/day LDE225 has been shown to penetrate the blood brain barrier, inhibit Gli1 mRNA expression, and prevent tumor growth in a medulloblastoma allograft mouse model. This compound has been investigated in phase II clinical trials for potential treatment of several Hh pathway activated cancers.Related product price
- Purmorphamine
₹14267.35-58054.48 - 329196-48-7
₹15209.13-61258.68 - Smoothened Agonist, HCl
₹21460
